Improved imaging for cancer radiation therapy
Evaluation of Improved Onboard Patient Imaging With the HyperSight Platform on TrueBeam 4.1
This study is testing a new imaging tool called 'HyperSight' to see if it can help doctors deliver radiation therapy more accurately for cancer patients while protecting healthy tissue.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Varian, a Siemens Healthineers Company Industry-sponsored |
| Drugs / interventions | radiation |
| Locations | 1 site (Baltimore, Maryland) |
| Trial ID | NCT06187103 on ClinicalTrials.gov |
What this trial studies
This study evaluates a novel cone beam computed tomography (CBCT) imaging solution called 'HyperSight' designed to enhance image-guided radiation therapy (IGRT) for various cancers. The approach aims to improve the precision of radiation delivery by addressing limitations of conventional CBCT technology, such as long acquisition times and poor image quality. By comparing real-time CBCT images with reference images, clinicians can make necessary adjustments to target tumors more accurately while minimizing exposure to healthy tissues. The study will involve patients receiving radiation therapy at the University of Maryland Medical Center.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with biopsy-confirmed malignancies requiring radiation therapy to specific areas such as the head and neck, breast, lungs, upper gastrointestinal structures, or pelvis.
Not a fit: Patients who are pregnant, have certain implanted devices, or are receiving very limited palliative radiation may not benefit from this study.
Why it matters
Potential benefit: If successful, this imaging technology could lead to more accurate radiation treatments, improving outcomes for cancer patients.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in improving imaging techniques for radiation therapy.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patient is willing and able to provide written consent. 2. Patient is at least 18 years of age at the time of consent. 3. Patient has biopsy confirmed malignancy and recommendation for definitive or palliative radiation to the head and neck, breast, lungs, upper GI structures, or pelvis. 4. Patient has ECOG performance status 0-2. 5. Patient will be receiving radiation therapy at University of Maryland Medical Center, Department of Radiation Oncology. Exclusion Criteria: 1. Patient is pregnant or attempting pregnancy. 2. Patient has implanted cardiac devices or nerve stimulation devices. 3. Patient has known genetic pre-disposition for sensitivity to radiation (e.g., Li Fraumeni). 4. Patient receives palliative radiation for 5 or fewer fractions. 5. Patient is part of a vulnerable population (per ISO 14155:2020, "individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response"). This includes prisoners.
Where this trial is running
Baltimore, Maryland
- University of Maryland Medical Center — Baltimore, Maryland, United States (Recruiting)
Study contacts
- Study coordinator: Sean Davidson
- Email: sean.davidson@varian.com
- Phone: 437-991-8294
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.